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           Nowadays, infections of the HBV and HCV are one of the major global 
public health problem. The objective of this study was to determine the 
prevalence of HBV and HCV virus from the first six months of 2020 in the of Erbil 
province, Kurdistan region of Iraq. Also associations between the prevalence of 
HBV and HCV in different age groups, has been established. 
  The study was conducted on (101) individuals (63 males and 38 females), of 
different aged population groups, in Erbil city from beginning of January 2020 to 
the end of June 2020. To detect the positive results of both HBV and HCV (VL), all 
samples subjected to detect their viral load by GeneXpert (RT PCR or RTqPCR). 
Out of (101) samples, 24(%23.76) of HBV and 7(%6.93) for HVC in both sex were 
detect positive respectively. Prevalence of both HBV and HCV was highest in 
males than females. Also the highest percentage of HBV found between (19-40) 
years, 12(%19.04) in males and 5(%13.15) in females. In addition highest number 
of HCV positive was found between (41-60) years, which 2(%3.17) and 2(%5.26) 
for males and females respectively, while opposite results were found from 
other aged groups 
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Viral hepatitis B and C viruses (HBV and HCV) are responsible for the majority of 
chronic liver disease worldwide (Villar et al., 2015). An infected individual spreads the 
viruses in contaminated blood and body fluids to an uninfected individual (Pardee 2019). 
Worldwide, there are over 350 million people with chronic HBV (Hebo et al., 2019). Of the 
approximately 2 billion exposed, more than 600 000 deaths annually; 170 million have 
chronic HCV, with nearly 500 000 deaths annually (Kateera et al., 2015). HBV infection 
prevalence varies significantly by geographic area, ranging from 0.1% to 20% in different 
parts of the world and from 2% to 8% in countries with intermediate endemicity for 
hepatitis B infection (Tozun et al., 2015). 
 Infections of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are typically 
asymptomatic for decades, and proactive screening can avoid liver disease through prompt 
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diagnosis and treatment. More reliable estimates of the general population and risk groups 
for chronic HBV and HCV infections are required (Kanda et al. , 2019). The number of deaths 
caused by the majority of communicable diseases, hepatitis mortality rates worldwide, rose 
from 0.89 million in 1990 to 1.45 million in 2013 (Moradi et al., 2019). Few reproducible 
mortality studies have been carried out in patients with autoimmune hepatitis (AIH) and its 
variants (van et al. ,2019). 
Recently, an epidemiological study of HBV and HCV infection has been performed 
among individuals between the ages of 10 and 69 living in the five geographic regions of 
Brazil, with average HBsAg, anti-HBc and anti-HCV seroprevalence levels of 0.37%, 7.4% and 
1.38% respectively (Villar et al., 2014). The plan of the global health sector at the WHO to 
eradicate Viral Hepatitis as a major threat to public health by 2030 needs significant efforts 
from governments, health authorities and communities. To help control the number of 
people living with Hepatitis B Virus (HBV) (WHO 2016), service provision needs to be 
increased. Just 5 million of the estimated 71 million people diagnosed with HCV have 
currently been treated (Popping et al. ,2020). Several research showed that in the first years 
of injection drug use, the incidence of HCV was greatest, but little is known about health 
seeking actions (Enkelmann et al. ,2020). 
 
Materials and Methods 
Sample Collection  
A total of 101 blood samples were collected from suspected patients, who visited 
the private clinical sectors, from 1 January to 30 June 2020. 10 mL of blood was drawn from 
each suspected patients. 5 mL of the blood samples collected inside the gel tube, after 
clotting, centrifuged them for 15 minutes at 5000 rpm. Other remained 5 mL of blood 
collect inside the (EDTA) tube, centrifuged as mentioned above. A questionnaire was also 
prepared and used to gather personal data (name (optional), age, and gender) for each 
case. The samples separated regarding to their gender to (63 males and remains were 
females), and their ages in to four specific age groups (6-18, 19 -40, 41 -60 and 61 -86).  
 
HBV and HCV Viral Load Detection 
Blood samples subjected for detection of HBV and HCV viral load by Real-Time qPCR 
(Real-Time Quantitative PCR) technology. Regarding to the manufacture instructions catalog 
number GXHBV-VL-CE-10 targets for HBV DNA, and catalog number GXHCV-VL-CE-10 targets 
for HCV RNA ,used for screening and diagnose the viral load of both virus in our samples. For 
detection of HBV (0.6-1mL plasma EDTA) for HCV (1mL of plasma of EDTA) added to their 
cartridges, by using 1mL micropipette with disposable pipette. Cartridges loaded inside the 
GeneXpert instrument, which it is full automate system and integrate specimen purification, 
nucleic acid amplification, and detection of the target sequence in simple or complex 
specimens using real-time reverse transcriptase PCR (RT-PCR) and (RT-qPCR) which uses 
fluorescence to detect the RNA and DNA of interest viruses. The systems require the use of 
single-use disposable GeneXpert cartridges that hold the RT-PCR reagents and host the RT-
PCR processes. 
Xpert HCV and HBV Viral Load cartridge includes reagents for the detection of HCV 
RNA and HBV DNA in specimens as well as two internal controls used for quantitation of 
HCV RNA and HBV DNA. The internal controls (High and Low) Internal Quantification 
Standards (IQS-H/IQS-L) monitor recovery and the presence of inhibitor(s) in the RT and PCR 
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reactions. To verifies that the correct volume of sample has been added in the sample 
chamber and ensure the sample was correctly added to the cartridge system has Sample 
Volume Adequacy (SVA) control. Also the Probe Check Control (PCC) verifies reagent 
rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability. Because the 
cartridges are self-contained, cross contamination between samples is minimized. The 
results are interpreted automatically by the GeneXpert Instrument System from measured 
fluorescent signals. Regarding to WHO reference material for plasma and serum samples 
limitation by geneXpert system reported as 3.20 IU/mL, 5.99 IU/mL respectively for linear 
range quantification 10 to 109 IU/mL for HBV and 10 to 108 IU/mL for HCV (WHO 2016). 
 
Statistical Analysis 
The chi-square was applied to examine the relationship between the prevalence of 
HBV and HCV from different sexes and to determine the association the prevalence of HBV 
and HCV among different aged gropes. P-values < 0.05 were considered to be statistically 
significant.     
 
Results 
Table 1.  prevalence of HBV and HCV according to gend 
 
 Table 2.  prevalence of HBV according to four specific age groups 
 
Viruses Number of screened % positive P 
value Males Females Total Males Females Total 
HBV 63(%62.37) 38(%37.62) 101(%100) 19(%30.1) 5(%13.15) 24(%23.76) 0.004 
HCV 63(%62.37) 38(%37.62) 101(%100) 3(%4.76) 2(%5.12) 7(%6.93) 0.654 
Gender  Different  age groups % HBV positive %  P value  
6-18 19-40 41-60 61-86 Total  6-18 19-40 41-60 61-86 Total  
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Figure 2. Prevalence of HBV according to four specific groups 
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Figure 3. Prevalence of HCV according to four specific groups 
 
Discussion  
Infection with the hepatitis B virus ( HBV) and hepatitis C virus ( HCV) is a public 
health problem (Police et al. ,2020). Many men, 40-80% live with chronic hepatitis B or C, 
are unaware of their serostatus, and remain infectious to others (Ayele et al. ,2020). Recent 
data have shown that about 350 million people are chronically infected with HBV and 
around 200 million are infected with HCV (Hussein et al . ,2017). 
In recent years, more and more data have been developed in developing countries 
and high/intermediate endemic areas where the most common route of infection is still 
vertical transmission from mother to child, and horizontal transmission between children , 
particularly siblings (Franco et al., 2012). Previous data from 2006 to 2009 suggest that a 
low prevalence of hepatitis B and hepatitis C infection exists in Iraq's capital city Baghdad 
(Ataallah et al., 2011). It also reported similar results in Basra (Al-Rubaye et al . , 2016). HBV 
and HVC prevalence are investigated in Erbil (Taher et al. ,2020). 
The prevalence of hepatitis B surface antigen (HBsAg) and HCV antibody (anti-HCV) 
was identified in the Turkish population as 2.3% and 0.37% respectively (Yakaryilmaz et al., 
2006). At the national level, the age-standardized prevalence of hepatitis B in Iran fell from 
3.02 % (95 % uncertainty interval; 2.26 to 3.96) in 2000 to 1.09 % (95 %uncertainty intervals; 
0.85 to 1.37) in 2016, with a cumulative improvement of -64.84 %. In 2016 the prevalence of 
hepatitis B in males was more than 1.3 times greater than in females (Rezaei et al. ,2020).  
The total number of screened for HBV and HBC were 101 blood samples, 63(%62.37) 
of them were males and 38(%37.62) were females.  The present study indicated that %23.76 
in males and %13.15 in females of the samples were positive for HBV, while the number of 
HCV positive dramatically decreased to %4.76 in males and %5.12 in females. For both 
viruses statistically showed significant for  HBV the p-value was   0.004, whereas for HCV 
was non-significant and the p-value 0.654. (table 3.1 and figure 3.1). Although the 
prevalence of HBV and HCV among diabetic patients is higher, it has a low prevalence 
compared with other patients studied (Merza et al. ,2020). At 1992 epidemiology estimated 
that the prevalence of HBsAg in the general Chinese population was 75 % (Said et al . , 
2019). Chronic hepatitis B patients reported slightly lower health-related life scores in 
various areas relative to stable control subjects in the province of AL-Najaf / Iraq (Kadhim et 
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al. ,2020). 
There are 3 prequalified rapid diagnostic assays for hepatitis B surface antigen 
(HBsAg) by WHO that is responsive, accurate, and effective in HBV screening: SD Bioline, 
Determines 2, and VIKIA. POCTs are less accurate and sensitive to other biomarkers but 
have some applicability. The GeneXpert HBV viral load assay is sensitive and specific with a 
wide range of dynamics (Jackson et al. ,2020). The HBV DNA quantification is used to initiate 
and monitor antiviral treatment (Abravanel et al. ,2020). The GeneXpert HBV-VL test, which 
has the potential for near-point molecular treatment testing, showed excellent performance 
and proved to be a reliable tool for quantification of HBV DNA (Khodare et al. ,2020). The 
research found a seroprevalence rate of 13.3 % of HBeAg among prospective asymptomatic 
blood donors (Rufai et al., 2014). 
In our results showed that there are association among the different aged group that 
infected by HBV in male, the statistical of p-value was  0.0007, the highest number was 19-
40 aged groups 12(%19.04) while in 41-60 ages were 5(%7.93) .On the other hands for two 
other remains groups have the lowest number of positive HBV 1(%1.58) respectively .In 
female the prevalence of HBV positive has the largest number was 5(%13.15) in aged groups 
19-40 years and three other groups there were no any infected HBV positive and statistically 
significant ( table 3.2 and figure 3.2).    HBV prevalence at 2.2% and carrier rate at 0.3% in 
men and 0.1% in women (Goudeau et al., 1995). At first sex, the number checked and those 
positive in the age group is as follows: < 10 years (7/25), 11-14 years (24/143), 15-18 years 
(76/433), 19-22 years (14/103), > 23 years (2/16)(Forbi et al., 2008). The prevalence of 
hepatitis B surface antigen (HBsAg) and total anti-HBc (core) was 6.8% and 35.6% in Turkish 
,Kurds, and 2.2% and 12.7% in Iraqis respectively (Chironna et al., 2003). Based on the 
prevalence in the general population of carriers of hepatitis B surface antigen, countries are 
classified as high (> 8%), intermediate (2-7%) or low (< 2%) endemic. Iraq is among the 
middle prevalence countries (Hussein et al., 2015). Also, approximately 5% of the general 
population in western Iran has previous HBV exposure and less than 1% is HBsAg carrier 
(Alavian et al., 2012). The prevalence of hepatitis B surface antigen (HBsAg) varies according 
to different reports, but in Iranian provinces, a prevalence of 1.2%-5% was registered (Ziaee 
et al . , 2016). 
At the point of care, molecular testing can turn out to be a game-changer for HCV 
diagnosis and treatment monitoring through increased sensitivity, reduced turnaround 
time, and performance ease. One such assay has recently been released on GeneXpert 
(Gupta et al., 2017). Although the RNA point-of-care technology for novel hepatitis C virus 
(HCV) has the potential to improve diagnosis in resource-limited settings (Mohamed et al. 
,2020). Viral load GeneXpert HCV (within 105 minutes). (Latham et al., 1998). For GeneXpert  
HCV Viral Load and venipuncture blood samples, finger-stick whole-blood samples were 
used (Bajis et al . , 2019; Calvaruso et al., 2019; Saludes et al., 2020). Regarding HCV 
infection 3(%4.76) for different aged groups mostly between 41-60 years, their prevalence 
was 2(%3.17) and it is higher than from other groups and statistically significant in males the 
p-value was 0.0008. However for female groups all positive HCV in 41-60 aged groups 
(2(%5.26) and cannot find any positive HCV from reaming groups, therefor statistically no 
significant and its p-value was  0.11 (table 3.3 and figure 3.3). In Iraq HCV prevalence rises 
dramatically with maternal age, women around 30 years of age are considered to be a risk 
group for HCV infection (Al-Kubaisy 2012).evelopment are people who tend to be lazy and 
do not care about their environment. 
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Conclusions 
We have shown that nearly a quarter of the blood sample positive for HBV is also 
positive for HBV, a marker of active viral replication and transmission, which can be taken as 
an indicator of active HBV in Erbil individuals. In addition, the prevalence of HCV in these 
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